A new class of nonhormonal pregnancy-terminating agents. Synthesis and contragestational activity of 3,5-diaryl-s-triazoles
摘要:
A series of 3,5-diaryl-s-triazoles were synthesized and evaluated as postimplantation contragestational agents. The introduction of various substituents (e.g., an o-alkyl chain on one phenyl and a m-alkoxy group on the other) was found to increase the potency. Several compounds with very high pregnancy-terminating activity in both hamsters and rats were obtained. One of these, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-s-triazole, DL 111 (36), was selected for detailed evaluation in various animal species. A synthetic scheme for the preparation of these compounds and preliminary structure-activity relationships are presented.
合成了一系列香豆素连接的噻唑 ( 6a–p ),并针对与癌症有关的人类碳酸酐酶 (hCA) IX 和 XII 对合成化合物进行了评估。所有化合物都表现出对两种亚型的选择性抑制。设计的化合物在适度纳摩尔至亚微摩尔范围内抑制 hCA IX。hCA XII 在低至中等纳摩尔范围内受到抑制。化合物6o表现出对 hCA XII 的最佳抑制作用,其K i值为 91.1 nM。化合物6o的水解形式也表现出良好的相互作用以及与这两种亚型的良好对接分数。因此,该化合物可以作为设计选择性和有效的 hCA XII 抑制剂的模板。
[EN] OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET D'INDOLE SUBSTITUÉS PAR DE L'OXADIAZOLE ET OXAZOLE COMME INHIBITEURS DE DGAT1
申请人:NOVARTIS AG
公开号:WO2009040410A1
公开(公告)日:2009-04-02
The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.
Iodine-mediated one-pot intramolecular decarboxylation domino reaction for accessing functionalised 2-(1,3,4-oxadiazol-2-yl)anilines with carbonic anhydrase inhibitory action
作者:Srinivas Angapelly、P. V. Sri Ramya、Rohini Sodhi、Andrea Angeli、Krishnan Rangan、Narayana Nagesh、Claudiu T. Supuran、Mohammed Arifuddin
DOI:10.1080/14756366.2018.1443447
日期:2018.1.1
Fluorescence properties of some of the representative molecules obtained in this way were studied. The synthesised 2-(1,3,4-oxadiazolo-2-yl)aniline-benzene sulphonamides (8a-o) were screened for their carbonic anhydrase (CA, EC 4.2.1.1) inhibitoryactivity. Most of the compounds exhibited low micromolar to nanomolar activity against human (h) isoforms hCA I, hCA II, hCA IV, and XII, with some compounds displaying
The present invention provides compounds of the following structure;
A-Q-B—C-D
that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.